<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/9865118#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction9" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction7" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction8" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction5" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction6" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction3" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction11" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction4" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction10" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction1" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction2" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Isovaleric acidemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Isovaleric acidemia is an inborn error of metabolism that arises due to mutations in isovaleryl-CoA dehydrogenase (IVD), a mitochondrial enzyme that catalyzes the third step in the catabolic pathway for leucine, the conversion of isovaleryl-CoA and FAD to  beta-methylcrotonyl-CoA and FADH2 (Tanaka et al, 1966; Finocchiaro et al. 1978; Rhead and Tanaka 1980). Isovaleric acidemia has variable clinical presentation and lacks a clear correspondence between genotypic alterations and phenotypic outcome (Vockley and Ensenauer, 2006). Symptoms include vomiting, seizures, low energy, and a characteristic sweaty foot odor due to presence of isovaleric acid, 3-hydroxyisovaleric acid, isovarleryl-glycine and isovaleryl-carnitine in blood and urine (Vockley et al, 1991; Mohsen et al, 1998; Zaki et al, 2017; Dercksen et al, 2012; D&apos;Annibale et al, 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of branched-chain amino acid catabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the genes that encode enzymes responsible for the catabolism of the branched-chain amino acids leucine, isoleucine and valine give rise to a number of inborn errors of metabolism (IEMs). Although IEMs are individually rare, collectively they are relatively common with an estimated overall prevalence of ~1:800 live births (Mak et al, 2013). The frequency of particular IEMs is also highly variable across different populations, a result in part of founder effects in closed populations. For instance, although the overall frequency of Maple Syrup Urine disease is 1:185,000 live births (Strauss et al, 2020), the frequency rises to 1:380 in some Old Order Mennonite communities (Fisher et al, 1991). Accumulation of toxic intermediary metabolites causes a range of clinical phenotypes in patients with IEMs including metabolic acidosis, vomiting, seizures, psychomotor and developmental delays and death (reviewed in Schrier Vergano et al, 2022; Holo&#269;ek, 2018; Neinast et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Branched-chain ketoacid dehydrogenase kinase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Branched-chain ketoacid dehydrogenase kinase deficiency (BCKDKD) is a neurological disorder that arises due to mutations in branched-chain ketoacid dehydrogenase kinase (BCKDK) (Joshi et al 2006; Novarino et al, 2012; Garcia-Cazorla et al, 2014; Tangeraas et al, 2023). BCKDK is a negative regulator of the branched-chain ketoacid dehydrogenase complex (BCKDH), the enzyme responsible for oxidative decarboxylation of branched-chain amino acid derivatives. BCKDK-dependent phosphorylation of serine residues in the E1 alpha subunit of the enzyme BCKDHA inactivates the BCKDH (Popov et al, 1992; Li et al, 2004; Wynn et al, 2004). Inactivating mutations of BCKDK are associated with impaired intellectual development, microencephaly and autism (Joshi et al 2006; Novarino et al, 2012; Garcia-Cazorla et al, 2014; Tangeraas et al, 2023). Consistent with the role of BCKDK in inhibiting BCKDH activity, inactivating mutations in BCKDK result in higher levels of BCKDH activity and reduced BCAAs in plasma, tissues and urine in mouse models, patients and cell lines (Joshi et al, 2006; Novarino et al, 2012). Symptoms of BCKDK deficiency are alleviated in mouse models by dietary supplementation with a BCAA-enriched diet (Joshi et al, 2006; Novarino et al, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-methylglutaconic aciduria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in AUH are associated with 3-methylglutaconic aciduria, a rare autosomal recessive disorder. AUH catalyzes the fifth step in the catabolism of leucine, the conversion of 3-methylglutaconyl-CoA to 3-hydroxy-methylglutaryl-CoA (Iljst et al, 2002; Ly et al, 2003; Mack et al, 2006). Mutations that affect AUH stability or function result in accumulation of metabolic intermediates such as 3-methylglutaconic acid, 3-methylglutaric acid and 3-hydroxyisovaleric acid that are excreted in urine (Duran et al, 1982; Ly et al, 2002; Mack et al, 2006; Nardecchia et al, 2022). The clinical presentation of 3-methylglutaconic aciduria is variable ranging from no-to-mild symptoms to severe encephalopathy, metabolic acidosis and coma (Nardecchia et al, 2022). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-hydroxyisobutyryl-CoA hydrolase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-hydroxyisobutyryl-CoA hydrolase deficiency is an autosomal recessive inborn error of metabolism caused by mutations in HIBCH, a mitochondrial enzyme that catalyzes the fifth step of the valine catabolic pathway (Hawes et al, 1996; Brown et al, 1982; Loupatty et al, 2007). Like mutations in ECHS1, the enzyme that catalyzes the third step of valine metabolism, HIBCH mutations result in accumulation of toxic metabolic intermediates and manifest clinically with severe psychomotor and developmental delays, neurodegeneration and brain lesions, characteristic of a Leigh-like syndrome (Brown et al, 1982; Loupatty et al, 2007; Ferdinandusse et al, 2013; Peters et al, 2015; Reuter et al, 2014; D&apos;Gama et al, 2020; reviewed in Rahman et al, 2023).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
 <bp:stepProcess rdf:resource="#Catalysis10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
 <bp:stepProcess rdf:resource="#Catalysis11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
 <bp:stepProcess rdf:resource="#Catalysis1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#Catalysis6" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#Catalysis7" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
 <bp:stepProcess rdf:resource="#Catalysis2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#Catalysis8" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#Catalysis9" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IVD mutants don&apos;t synthesize beta-methylcrotonyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AUH mutants don&apos;t synthesize 3-hydroxy-methylglutaryl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
 <bp:stepProcess rdf:resource="#Catalysis4" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DBT loss-of-function mutants don&apos;t synthesize BCAA-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACAT1 mutants don&apos;t synthesize propionyl-CoA or acetyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DLD cause MSUD3/DLDD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the dihydrolipoyl dehydrogenase (DLD) gene are associated with dihydrolipoyl dehydrogenase deficiency (DLDD), an autosomal recessive disorder characterized by lactic acidosis and neurological deterioration (reviewed in Quinonez et al, 2021). DLDD is sometimes referred to as Maple Syrup Urine Disease 3 due to its effects on BCKDH function, but the phenotype is distinct due to the involvement of DLD in multiple protein complexes (reviewed in Strauss et al, 2020). DLD encodes the shared E3 component of the multiprotein mitochondrial enzymes BCKDH (branched-chain amino acid dehydrogenase), KGDH (alpha-ketoglutarate deydrogenase) and PDH (pyruvate dehydrogenase). In consequence mutations in DLD have pleiotropic effects and manifest with a range of clinical outcomes, including increased urinary excretion of alpha-keto acids and accumulation of pyruvate and plasma branched-chain amino acids in plasma (reviewed in Quinonez and Thoene, 2021). Mutations in DLD often occur as compound heterozygotes complicating the assignment of pathogenic effect. Moreover, the severity of phenotypic effects displayed in vivo does not correlate linearly with the extent of residual DLD enzymatic activity in vitro (Shany et al, 1999; Cameron et al, 2006; Quinonez et al, 2013; reviewed in Quinonez and Thoene, 2021).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function DLD mutants don&apos;t dehydrogenate dihydrolipoyl DBT</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">H139Hfs13* PPM1K does not dephosphorylate BCKDH</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in either of the protein subunits of the E1 decarboxylase subcomplex of BCKDH are associated with Maple Syrup Urine Disease 1 (MSUD1). Mutations of residues in BCKDHA that participate in subunit associations or that form part of the hydrophobic core destabilize the overall assembly of BCKDH and are associated with classic Maple Syrup Urine Disease 1A (Aevarsson et al, 2000; reviewed in Straus et al, 2020; Biswas et al, 2019). Mutations of BCKDHA with less drastic effects on structural  stability of the overall BCKDH complex are generally associated with intermediate or intermittent forms of MSUD, and are not annotated in this pathway (reviewed in Strauss et al, 2020)  Mutations in BCKDHB appear to be causative in 35% of MSUD cases(reviewed in Strauss et al, 2020). Classic Maple Syrup Disease 1B is associated with severe loss-of-function mutations in BCKDHB that destabilize the protein interaction interfaces and compromise structural integrity of the complex (reviewed in Straus et al, 2020; Biswas et al, 2019).  Less detrimental mutations in BCKDHB are not annotated in this pathway and are generally associated with intermediate or intermittent forms of MSUD (reviewed in Strauss et al, 2020).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-Methylcrotonyl-CoA carboxylase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-methylcrotonyl-CoA carboxylase catalyzes the reversible conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, the fourth step in the catabolism of leucine (Chu et al, 2007; Son et al, 2020). MCCC is composed of two subunits encoded by MCCC1 and MCCC2. MCCC1 protein is covalently attached to a biotin moiety that is essential for the ATP dependent carboxylation activity, while MCCC2 contributes carboxyltransferase activity (Holzinger et al, 2001; Lau et al, 1979; Gallardo et al, 2001; Baumgartner et al, 2001). Mutations in either subunit of the enzyme, MCCC1 and MCCC2, are associated with 3-methylcrotonyl-CoA carboxylase deficiency (MCCD), also known as 3-methylcrotonylglycinuria, an autosomal recessive inborn error of metabolism characterized by accumulation and excretion of 3-hydroxyvaleric acid and 3-methylcrotonylglycine (Bannwart et al, 1992; Lehnert et al, 1996; Baumgartner et al, 2005). MCCD is the most prevalent organic aciduria with frequencies ~ 1:50,000 but has variable clinical phenotypes. 1-2% of affected individuals are at risk of a severe adverse effect that manifests during the neonatal period with severe neurological impairment while ~10% of affected individuals develop only minor symptoms (Baumgartner et al, 2001; Gallardo et al, 2001; Gruenert et al, 2012). Mutations in MCCC1 and MCCC2 have been identified that affect the stability or activity of the alpha or beta subunit, occasionally by compromising the essential biotinylation of the protein (Gallardo et al, 2001; Grunert et al, 2012; Fonseca et al, 2016; Dantas et al, 2005 ; Steen et al, 1999; Morscher et al, 2012 ; Baumgartner et al, 2001; 2004; Uematsu et al, 2007; Holzinger et al, 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MCCC mutants don&apos;t synthesize beta-methylglutaconyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCKDHA or BCKDHB loss-of-function mutants don&apos;t synthesize BCAA-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mitochondrial short-chain enoyl-CoA hydratase deficiency 1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ECHS1 (short-chain enoyl-CoA hydratase, also known as SCEH) is a mitochondrial enzyme that plays roles in fatty acid oxidation and valine metabolism (Yamada et al, 2015). In the branched-chain amino acid catabolism pathway, ECHS1 has specificity for the valine derivative methylacrylyl-CoA, but can also act on the leucine derivative 3-methylcrotonyl-CoA. ECHS1 binds to the isoleucine derivative tiglyl-CoA, but does not appreciably catalyze its hydration (Yamada et al, 2015; Ferdinandusse et al, 2015). Homozygous mutations in ECHS1 are associated with a severe Leigh-like disorder, characterized by cardiac aberrations, encephalopathy and epilepsy and severe developmental and neurological delays, likely arising at least in large measure from the accumulation of toxic levels of methylacrylyl-CoA (Peters et al, 2014; Haack et al, 2015; Yamada et al, 2015; Ferinandusse et al, 2015; Sakai et al, 2015; Tetreault et al, 2015; Kohda et al, 2016; Fitzsimmons et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Beta-ketothiolase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACAT1 is a mitochondrial enzyme that plays a role in metabolism of ketone bodies and isoleucine catabolism (Fukao et al, 1991; Haapalainen et al, 2007; reviewed in Fukao et al, 2019). As part of isoleucine catabolism in the mitochondria, ACAT1 catalyzes the thiolytic degradation of alpha-methylacetoacetyl-CoA to propionyl-CoA and acetyl-CoA (Fukao et al, 1991; Happalainen et al, 2007). Mutations in ACAT1 that affect protein stability and enzymatic activity are associated with beta-ketothiolase deficiency, also known as alpha-methylacetoacetic aciduria, an inborn error of metabolism that is identified by the presence of isoleucine intermediate metabolites in bodily fluids (Daum et al, 1973; Schutgens et al, 1982; Fukao et al, 1991; Fukao et al, 1992; Wakazono et al, 1995; Fukao et al, 1998; Sakurai et al, 2007; reviewed in Korman, 2006; Fukao et al, 2019). Neonatal onset is rare and most affected individuals present between 6 and 18 months with metabolic acidosis, lethargy, vomiting and sometimes coma (reviewed in Korman, 2006). As with other disorders of branched-chain metabolism, there is not a direct correlation between genotype and severity of phenotypic presentation (reviewed in Korman, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCKDK loss-of-function mutations do not phosphorylate BCKDH</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maple Syrup Urine Disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The branched-chain alpha ketoacid dehydrogenase complex (BCKDH) catalyzes the oxidative decarboxylation of branched-chain keto acids in the mitochondrial matrix as the second step in the degradation of branched-chain amino acids (BCAAs) leucine, valine and isoleucine, providing acetyl CoA and succinyl CoA intermediates for the Krebs Cycle (reviewed in Strauss et al, 2020; Zhang et al, 2023).  BCKDH is a multi-enzyme complex consisting of three sub-complexes, the E2 transacylase, the E1 decarboxylase and the E3 dehydrogenase. The core of BCKDH is the E2 transacylase domain, made up of 24 copies of Dihydrolipoamide Branched-chain Transacylase (DBT) arranged in octahedral symmetry. Surrounding the E2 core are 12 copies of the E1 decarboxylase tetramer (each of which consists of a dimer of BCKDHA and a dimer of BCKDHB) and six copies of the E3 dehydrogenase (each consisting of a dimer of Dihydrolipoyl Dehydrogenase (DLD)). The E3 subcomplex is not specific to BCKDH but is also a component of the pyruvate dehydrogenase complex (PDC) and the alpha-ketoglutarate dehydrogenase complex (alpha-KGDC) (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000; reviewed in Biswas et al, 2019; Strauss et al, 2020).  In addition to the E1, E2 and E3 components, the BCKDH complex also depends on other cofactors- lipoamide for the function of the E2 transacylase, thiamine diphosphate and potassium for the function of the E1 decarboxylase and FAD and NAD+ for the function of the E3 dehydrogenase (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000; reviewed in Biswas et al, 2019; Strauss et al, 2020).  The activity of BCKDH is regulated by the association of BCKD kinase (BCKDK) and protein phosphatase 1K (PPM1K) with the macromolecular complex (Reed et al, 1985). Phosphorylation of BCKDHB S342 by BCKDK inhibits the catalytic activity of BCKDH, while PPM1K-mediated dephosphorylation activates it (Li et al, 2004; Wynn et al, 2004; Wynn et al, 2012). BCKDK is itself negatively regulated by thiamine (Chuang et al, 2006).  Structures for each of the subcomplexes of human BCKDH have been solved, and the complex has a total molecular mass on the order of 4 million Da (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000).  Loss-of-function mutations in the BCKDHA, BCKDHB and DBT genes disrupt the stability and the activity of the BCKDH complex, causing an accumulation of branched-chain keto-acids that causes the characteristic odor associated with Maple Syrup Urine disease (MSUD), an inborn error of metabolism with a prevalence of 1:185,000 live births (reviewed in Strauss et al, 2020; Biswas et al, 2019). MSUD is an autosomal recessive disorder and in its classic neonatal form is characterized by a maple syrup odor to the urine, poor feeding, mental and physical retardation, lethargy, seizures, coma and death. Classic MSUD, like the intermediate, intermittent and thiamine-responsive forms described below, may arise as a result of mutations in any of BCKDHA, BCKDHB or DBT. Classic MSUD is characterized by the lowest (~0-3%) residual enzymatic activity of all the forms, and presents clinically during the neonatal period. An intermediate form (residual activity ~3-30%) manifests clinically many months after birth with signs of mental retardation and developmental delay. Patients with the intermittent form of MSUD have normal levels of BCAA and BCKA and normal development and physiology while healthy, but are triggered into manifesting symptoms of MSUD when stressed by, for instance, infection. The existence of a thiamine-responsive form of MSUD, in which symptoms are alleviated by dietary thiamine, is somewhat controversial, but may reflect the inhibitory effect of thiamine on BCKDK, relieving inhibition of BCKDH activity (Chaung et al, 2006; reviewed in Strauss et al, 2020, Biswas et al, 2019). Mandatory newborn screening programs include testing for MSUD, allowing for early intervention that is especially critical in cases of classic MSUD (Strauss et al, 2020)  Mutations in DLD, the E3 subunit shared with PDH and alpha-KGDH, affect the enzymatic activity of all three complexes and are responsible for a more severe disorder called dihydrolipoamide dehydrogenase deficiency (DLDD). DLLD generally results in death in infancy due to lactic acidosis (Taylor et al, 1978; reviewed in Ambrus, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ECHS1 mutants don&apos;t synthesize beta-hydroxyisobutyryl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DBT cause MSUD2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DBT disrupt the integrity of the E2 subunit of BCKDH, resulting in MSUD2 (reviewed in Strauss et al, 2020; Biswas et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">H139Hfs13* PPM1K causes a mild variant of  MSUD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPM1K is a mitochondrial protein phosphatase that removes the inhibitory phosphorylation from the E1 beta subunit of branched-chain ketoacid dehydrogenase (BCKDH) to restore BCKDH activity (Lu et al, 2007; Lu et al, 2009 a, b; Wynn et al, 2012; Zhou et al, 2012).  BCKDH is responsible for the oxidative decarboxylation of branched-chain amino acid (BCAA) derivatives of leucine, valine and isoleucine, providing acetyl CoA and succinyl CoA intermediates for the Krebs Cycle (reviewed in Strauss et al, 2020; Zhang et al, 2023). Loss-of-function mutations in subunits of BCKDH cause accumulation of toxic BCAAs in the urine, neurological defects and are the cause of Maple Syrup Urine disease (MSUD). More recently, a frameshift mutation in PPM1K was identified as the probable cause of a mild variant of MSUD (Oyarzabal et al, 2012). This frameshift introduces a stop codon at residue 151, destabilizing the protein, and transfection of PPM1K-deficient fibroblast lines with WT PPM1K restores BCKDH activity (Oyarzabal et al, 2012). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIBCH mutants don&apos;t synthesize beta-hydroxyisobutyrate</bp:displayName>
</bp:BiochemicalReaction>
</rdf:RDF>